Search Documents and Resources

documents

Financial Disclosure Report of New CDC Director, Rochelle Walensky International Code of Marketing of Breast-milk Substitutes

letters

CDC Failing on 9/11 Health Program Contracts POGO Urges the National Academies to Fix Its Conflict-of-Interest Policy POGO Opposes Califf Nomination Due to Conflicts of Interest Health Care Workers Need Federal Guidance on Their Whistleblowing Rights Public Comment on Nuclear Safety Board’s Access to Information EPA Lacks the Authority and Supporting Data to Propose Transparency Requirements for Science Advocates Applaud Bill Closing Whistleblower Loophole POGO Joins in Support of Worker Health and Safety Advisory Boards POGO Urges Congress Not to Confirm Nominee Who Used Nonprofit for His Own Benefit POGO Urges the President to Look at the Revolving Door as Part of Opioid Crisis Work POGO to Attorney General Sessions: Opioid Task Force Must Examine the Revolving Door POGO Comments on VA Rule Helping Some Camp Lejeune Victims POGO Urges Senate to Vote Against Nominee to the FDA POGO Asks President to Withdraw FDA Nominee POGO Calls for New Chairperson at Chemical Safety Board POGO to FDA on Conflicts of Interest: Disclose Them! POGO's Response to VA Inspector General's Subpoena for Whistleblower Records Public Comment on the Potential Release of Medicare Physician Data POGO Letter to Associate Commissioner Warner, FDA, Questioning FDA's Handling of Conflicts of Interest on FDA Advisory Committees POGO and Partners Oppose House Bill that Allows FDA More Secrecy POGO and Groups Support Better Information on Clinical Trials POGO Letter: FDA Advisors on Yaz and Yasmin Have Industry Ties POGO Letter Urges FDA Not to Weaken Conflict of Interest Standards at Center for Drug Evaluation and Research POGO Letter to FDA Commissioner Hamburg Concerning the Potentially Dangerous Interaction of the Drugs Seroquel and Methodone POGO's Letter to President Obama on Bioethics Commission Chair's Ghostwriting Practices POGO Letter to OMB Director Jacob Lew Regarding Proposed NIH Rule on Financial Arrangements between Researchers and Industry POGO Asks DHHS Secretary Sebelius to Reinvestigate FDA's Negligent Oversight of Unsafe Medical Devices POGO's fourth reply to letters from Dr. Schatzberg and Dr. Nemeroff POGO's third reply to letters from Dr. Schatzberg and Dr. Nemeroff POGO's second reply to letter from Dr. Schatzberg and Dr. Nemeroff POGO's first reply to letters from Dr. Schatzberg and Dr. Nemeroff POGO Letter to NIH on Ghostwriting Academics POGO Letter to NIH Director Francis Collins Again Urges Public Disclosure of Medical Researchers' Financial Ties to Industry POGO Letter to NIH Official on Possible Value of Testing Statins for Pandemic Flu POGO Letter to FDA Commissioner Margaret Hamburg Regarding Potentially Dangerous Drug Interaction Invovling Seroquel and Methadone POGO's letter to Deputy HHS IG on FDA's CDRH's low standard of medical devices approval The Finances Of FDA Advisory Committee Members: If Information Must Be Withheld, Let It Be Done Openly POGO letter to NIH Director Collins: Ethics reform at NIH needs a more ethical leader POGO Letter to DHHS on Pandemic Flu Vaccine: Answer Questions Instead of Dodging Them POGO Letter To NIH Director: Medical Researchers Should Be Made To Publicly Disclose Possible Conflicts Of Interest POGO Letter To NIH Director Francis Collins Urges Public Disclosure of Medical Researchers' Financial Ties To Industry POGO letter to Secretary Sebelius: Use emergency powers to support study on prevention of deaths from H1N1 flu POGO asks Secretary Sebelius to disclose mistakes that led to vaccine shortage POGO's letter to Commissioner Hamburg regarding medical devices POGO Letter to Secretary Sebelius regarding H1N1 Vaccine Shortage POGO letter to DHHS Secretary Sebelius: Greater transparency in the flu vaccine program is urgently needed POGO Letter to Secretary Sebelius Regarding Production of Vaccine for H1N1 Swine Flu POGO adds Public Comment regarding conflicts of interest among NIH grantees POGO Letter to FDA's Daniel Schultz MD regarding a policy decision by CDRH to discontinue inspections of nonclinical laboratories POGO Asks FDA Head to Have Deadly Syringe Incident Investigated POGO letter to FDA's Daniel Schultz MD regarding the lack of GLP inspections POGO Follow-up letter to CDRH Director Daniel Schultz POGO Letter to CDRH Director Daniel Schultz regarding a series of questions about the apparent decision not to enforce the GLP regulation POGO Letter to Senator Kennedy Regarding the Production of the Pandemic Flu Vaccine Scientists Who Serve Paid Consulting and Conflicts of Interest at NIH

resources

Oversight Provisions in the CARES Act: What they are, what they do, and how to make sure they work for Americans
    • Mission and Vision
    • Board & Staff
    • Financials
    • Contact Us
    • Privacy Policy
    • Donor Privacy Policy
    • Explore our work
    • Center for Defense Information
    • The Constitution Project
    • Congressional Oversight Initiative
    • Policy Letters
    • Reports
    • Testimony
    • For Oversight Staff
    • Whistleblower Resources
    • Report Corruption
  • Take Action
  • Sign Up
  • Donate
  • facebook
  • twitter
  • instagram
  • youtube
    • Mission and Vision
    • Board & Staff
    • Financials
    • Contact Us
    • Privacy Policy
    • Donor Privacy Policy
    • Explore our work
    • Center for Defense Information
    • The Constitution Project
    • Congressional Oversight Initiative
    • Policy Letters
    • Reports
    • Testimony
    • For Oversight Staff
    • Whistleblower Resources
    • Report Corruption
Project On Government Oversight
  • Take Action
  • Sign Up
  • Donate
  • Afghanistan
  • More Topics
  • About
  • Mission & History
  • Board & Staff
  • Financials
  • Take Action
  • For Federal Employees
  • COVID-19: Tips
  • Contact Us
  • Privacy Policy
  • Subscribe
  • Donate
Project On Government Oversight
    • Mission and Vision
    • Board & Staff
    • Financials
    • Contact Us
    • Privacy Policy
    • Donor Privacy Policy
    • Explore our work
    • Center for Defense Information
    • The Constitution Project
    • Congressional Oversight Initiative
    • Policy Letters
    • Reports
    • Testimony
    • For Oversight Staff
    • Whistleblower Resources
    • Report Corruption
  • Take Action
  • Sign Up
  • Donate

Public Health

Public Health

Latest

Now is the Appropriate Time for Congress to Spend Some Money to Make Some Change

analysis | July 22, 2022

Read

Latest

At Least Half of Panel Advising Congress on Drug Policy Had Undisclosed Ties to Drug Makers

investigation | October 28, 2021

Read
  • Discarded Drugs: Infrastructure Bill Leaves Cancer Patients by the Wayside

    investigation | September 29, 2021

  • Pulling Punches: Trump-Appointed Watchdog Suppressed White House-Related Probes

    investigation | April 20, 2021

  • America’s Transformative New Organ Donation Rule Goes into Effect Over Objections from Monopolistic Contractors

    investigation | April 5, 2021

  • Avoiding the Subject: On Pfizer Vaccine Quality Control, FDA Says Less than European Counterpart

    investigation | March 19, 2021

  • Hearing Without Listening

    analysis | December 16, 2020

  • FDA Panel Reviewing Pfizer Vaccine Leaves Out Some Experts Who Raised Concerns

    investigation | December 9, 2020

  • FDA Whitewashes Warnings About Coronavirus Vaccine Trials

    analysis | November 2, 2020

  • HHS, Inc.: Big Pharma Ties Draw Pandemic Response Concerns

    investigation | October 26, 2020

Previous 1 2 3 4 5 6 Next

Site Footer

  • facebook
  • twitter
  • instagram
  • youtube
  • Press Center
  • Contact Us
  • Careers
  • Briefing
  • Newsletters
  • Publications
  • Report Corruption
Better Business Bureau Accredited Charity CharityWatch Top Rated Charity Great Nonprofits 2021 Top-Rated Charity Navigator Four-Star Charity

©2023 POGO | Privacy Policy

Project On Government Oversight logo

Project On Government Oversight

Oversight in your inbox.